Use of drugs in the treatment of obesity

Annual Review of Nutrition

Volumn 17, Issue , 1997, Pages 383-403

  Atkinson, Richard L ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adverse events; Co morbidities; Medications

Indexed keywords

AMFEPRAMONE; BENZPHETAMINE; CHLORPHENTERMINE; CLORTERMINE; DEXAMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENMETRAZINE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE;

ADRENERGIC STIMULATION; DIETARY INTAKE; DISEASE SEVERITY; EPIDEMIC; EXERCISE; HUMAN; LIFESTYLE; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONINERGIC SYSTEM; TREATMENT PLANNING; WEIGHT REDUCTION;

ADRENERGIC AGENTS; ENERGY INTAKE; ENERGY METABOLISM; HUMANS; NEUROTRANSMITTER AGENTS; OBESITY; SEROTONIN AGENTS;

EID: 0030806823     PISSN: 01999885     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.nutr.17.1.383     Document Type: Review

References (76)

1. Abenhaim L, Monde Y, Brenot F, Rich S, Benichou J, et al. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335:609-16
2. Andersen T, Stokholm KH, Backer OG, Quaade F. 1988. Long-term (5-year) results after either horizontal gastroplasty or very-low calorie diet for morbid obesity. Int. J. Obes. 12:277-84
3. Atkinson RL. 1996. Mechanisms of weight loss with obesity surgery. In Progress in Obesity Research, ed. A Angel, C Bouchard, Vol. VII. London: Libbey
4. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA. 1995. Combined treatment of obesity. Obes. Res. 3(Suppl. 4):497-500S
5. Baez M, Kursar JD, Helton LA, Wainscott DB, Nelson DLG. 1995. Molecular biology of serotonin receptors. Obes. Res. 3(Suppl. 4):441-47S
6. Berger M. 1992. Pharmacological treatment of obesity: digestion and absorption inhibitors - clinical perspective. Am. J. Clin. Nutr. 55:318-195
7. Blundell JE, Lawton CL, Halford JCG. 1995. Serotonin, eating behavior, and fat intake. Obes. Res. 3(Suppl. 3):471-76S
8. Boozer CN, Brasseur A, Elhady AH, Atkinson RL. 1993. High fat diet promotes retention of body fat and increased LPL during food restriction. Am. J. Clin. Nutr. 58:846-52
9. Boozer CN, Schoenbach G, Atkinson RL. 1995. Dietary fat and adiposity: a dose-response relationship in adult rats fed isocalorically. Am. J. Physiol. 268:E546-50
10. Bouchard C, Perusse L. 1993. Genetics of obesity. Annu. Rev. Nutr. 13:337-54
11. Bouchard C, Perusse L. 1996. Current status of the human obesity gene map. Obes. Res. 4:81-90
12. Bray GA. 1976. The risks and disadvantages of obesity. In The Obese Patient, pp. 215-51. Philadelphia: Saunders
13. Bray GA. 1991. Barriers to the treatment of obesity. Ann. Intern. Med. 115(2):152-53
14. Bray GA. 1992. Peptides affect the intake of specific nutrients in the sympathetic nervous system. Am. J. Clin. Nutr. 55:265-71S
15. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. 1996. A double-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 4:263-70
16. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. 1993. Primary pulmonary hypertension and fenfluramine use. Br. Heart J. 70:537-41
17. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269:546-49
18. Coleman DL. 1978. Genetics of obesity in rodents. In Recent Advances in Obesity Research, ed. GA Bray, 2:142-52. London: New man
19. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, et al. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334:292-95
20. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. 1993. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int. J. Obes. 17(Suppl. 1):S73-78
21. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. 1991. Fluoxetine's effect on weight loss in obese subjects. Am. J. Clin. Nutr. 54:321-25
22. Dhurandhar NV, Atkinson RL. 1996. Comparison of serotonin agonists in combination with phentermine for treatment of obesity. FASEB J. 10:A561 (Abstr.)
23. Drent ML, van der Veen EA. 1993. Lipase inhibition: a novel concept in the treatment of obesity. Int. J. Obes. 17(4):241-44
24. Drent ML, van der Veen EA. 1995. First clinical studies with orlistat: a short review. Obes. Res. 3(Suppl. 4):623-25S
25. Enzi G, Baritussio A, Marchiori E, Crepaldi G. 1976. Short-term and long-term clinical evaluation of a non-amphetamine anorexiant (mazindol) in the treatment of obesity. J. Int. Med. Res. 4:305-17
26. Flatt JP. 1987. Effect of carbohydrate and fat intake on postprandial substrate oxidation and storage. Top. Clin. Nutr. 2:15-27
27. Goldstein DJ, Potvin JH. 1994. Long-term weight loss: the effect of pharmacologic agents. Am. J. Clin. Nutr. 60:647-57
28. Goldstein DJ, Rampey AH Jr, Dornseif BE, Levine LR, Potvin JH, Fludzinski LA. 1993. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes. Res. 1:92-98
29. Greenway FL. 1992. Clinical studies with phenylpropanolamine: a metaanalysis. Am. J. Clin. Nutr. 55(Suppl. 1):203-5S
30. Griffiths RR, Brady JV, Bradford LD. 1979. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. Adv. Behav. Pharm. 2:163-208
31. Grundy SM, Barnett JP. 1990. Metabolic and health complications of obesity. Dis. Mon. 36(12):641-731
32. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. 1989. International trial of long-term dexfenfluramine in obesity. Lancet 2:1142-45
33. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-46
34. Hartley GG, Nicol S, Halstenson C, Khan M, Pheley A. 1995. Phentermine, fenfluramine, diet, behavior modification, and exercise for treatment of obesity. Obes. Res. 3(Suppl. 3):340S (Abstr.)
35. Hudson KD. 1977. The anorectic and hypotensive effect of fenfluramine in obesity. J. R. Coll. Gen. Pract. 27:497-501
36. Inoue S, Egawa M, Satoh S, Saito M, Suzuki H, et al. 1992. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am. J. Clin. Nutr. 55:199-2025
37. Keesey RE, Powley TL. 1986. The regulation of body weight. Annu. Rev. Psychol. 37:109-33
38. Kramer FM, Jeffery RW, Forster JL, Snell MK. 1989. Long-term follow-up of behavioral treatment for obesity: patterns of regain among men and women. Int. J. Obes. 13:123-36
39. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. 1994. Increasing prevalence of overweight among US adults. JAMA 272:205-11
40. Leibowitz SF. 1995. Brain peptides and obesity: pharmacologic treatment. Obes. Res. 3(Suppl. 4):573-89S
41. Levitsky DA, Troiano R. 1992. Metabolic consequences of fenfluramine for the control of body weight. Am. J. Clin. Nutr. 55:167-72S
42. 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int. J. Obes. 19:678-85
43. Manson JE, Faich GA. 1996. Pharmacotherapy for obesity - do the benefits out-weigh the risks? N. Engl. J. Med. 335:659-60
44. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. 1990. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and nonbinge-eaters. Am. J. Psychiatr. 147:876-81
45. Mathus-Vliegen EMH, Van De Voore K, Kok AME, Res AMA. 1992. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake, and eating behaviour. J. Intern. Med. 232:119-27
46. McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, et al. 1994. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. Clin. Pharm. Exp. Ther. 269:792-98
47. McGinnis JM, Foege WH. 1993. Actual causes of death in the United States. JAMA 270:2207-12
48. Mei J, Erlanson-Albertsson C. 1996. Role of intraduodenally administered enterostatin in rats: inhibition of food. Obes. Res. 4:161-65
49. Natl. Task Force Prev. Treat. Obes. 1996. Long term pharmacotherapy in the management of obesity. JAMA 276:1907-15
50. Okada S, York DA, Bray GA, Erlanson-Albertsson C. 1991. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase selectively reduces fat intake. Physiol. Behav. 49:1185-89
51. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, et al. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-43
52. Perri MG. 1992. Improving maintenance of weight loss following treatment by diet and lifestyle modification. In Treatment of the Seriously Obese Patient, ed. TA Wadden, TB Van Itallie, pp. 456-77. New York: Guilford
53. Pi-Sunyer FX. 1993. Medical hazards of obesity. Ann. Intern. Med. 119:655-60
54. Pi-Sunyer X. 1995. Guidelines for the approval and use of obesity drugs. Obes. Res. 3:473-78
55. Ricaurte GA, Molliver ME, Martello MB, Katz JL, Wilson MA, Martello AL. 1991. Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 338:1487-88
56. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, et al. 1990. Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 323:1-6
57. Ryan DH, Kaiser P, Bray GA. 1995. Sibutramine: a novel new agent for obesity treatment. Obes. Res. 3(Suppl. 4):553-59S
58. Schutz Y, Munger R, Deriaz O, Jequier E. 1992. Effect of dexfenfluramine on energy expenditure in man. Int. J. Oben. 16(Suppl. 3):S61-66
59. Scoville BA. 1976. Review of amphetamine-like drugs by the Food and Drug Administration. In Obesity in Perspective, Fogarry Int. Cent. Adv. Stud. Health Sci., Ser. Prev. Med., ed. GA Bray, 2:441-43. Washington, DC: US Gov. Print. Off.
60. Shape Up Americal and Am. Obes. Assoc. 1996. Guidance for Treatment of Adult Obesity. Bethesda, MD: Shape Up Americal
61. Silverstone JT, Solomon T. 1965. The long-term management of obesity in general practice. Br. J. Clin. Prac. 19:395-98
62. Silverstone T. 1992. Appetite suppressants: a review. Drugs 43:820-36
63. Simopoulos AP, Van Itallie TB, 1984. Body weight, health and longevity. Ann. Intern. Med. 100:285-95
64. 3-adrenoceptor agonists in the treatment of obesity. Int. J. Obes. 20(Suppl. 4):4-5
65. Tauber-Lassen E, Damsbo P, Henriksen JE, Palmvig B, Beck-Nielsen H. 1990. Improvement of glycemic control and weight loss in type 2 (non-insulin-dependent) diabetics after one year of dexfenfluramine treatment. Diabetologia 33(Suppl.):A124 (Abstr.)
66. Thomas PR, ed. 1995. Weighing the Options. Criteria for Evaluating Weight-Management Programs. Washington, DC: Natl. Acad.
67. Toubro S, Astrup AV, Breum L, Quaade F. 1993. Safety and efficacy of long-term treatment with ephedrine, caffeine, and an ephedrine/caffeine mixture. Int. J. Obes. 17(Suppl. 1):S69-72
68. Troiano RP, Levitsky DA, Kalkwarf HJ. 1990. Effect of DL-fenfluramine on thermic effect of food in humans. Int. J. Obes. 14:647-55
69. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. 1989. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five year perspective. Int. J. Obes. 13(Suppl. 2):39-46
70. Weintraub M, et al. 1992. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin. Pharmacol. Ther. 51:581-646
71. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. 1984. A double blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144:1143-48
72. West DB, Fey D, Woods SC. 1984. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am. J. Physiol. 246:R776-87
73. Wilson GT. 1993. Behavioral treatment of obesity: thirty years and counting. Adv. Behav. Res. Ther. 16:31-75
74. Wurtman JJ, Wurtman RJ, Reynolds S, Tsay R, Chew B. 1987. Fenfluramine suppresses snack intake among carbohydrate cravers but not among non-carbohydrate cravers. Int. J. Eating Disord. 6:687-99
75. Yen TT. 1995. β-Agonists as antiobesity, antidiabetic and nutrient partitioning agents. Obes. Res. 3(Suppl. 4):531-36S
76. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman RM. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-31